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Objectives. This study sought to investigate hemostatic predic- 
tors of subacute occlusive coronary stent thrombosis. 
Background. Better hemostatic monitoring may improve anti- 
thrombotic therapy after stenting. 
Methods. In 140 consecutive patients undergoing Palmaz- 
Schatz stent implantation for suboptimal angioplasty results, we 
obtained serial blood samples immediately before and daily for 12 
days after stenting. We prospectively tested the hypothesis that 
subacute stent thrombosis was more frequent if the surface 
expression of the inducible fibrinogen receptor on platelets (flow 
cytometry) or the concentration of plasma fibrinogen or that of 
the prothrombin fragments Fl+ 2 before stent implantation ex- 
ceeded the 75th percentile of the entire study cohort. 
Results. All five stent occlusions encountered uring the study 
occurred in patients with platelet fibrinogen receptor expression 
above the 75th percentile. Thus, the rate of stent occlusion differed 
significantly between the groups defined by platelet fibrinogen 
receptor expression (14.3% vs. 0%, p = 0.0008). In both the group 
with fibrinogen concentration and that with F1+ 2 concentration 
above the 75th percentile, three stent occlusions occurred. Be- 
tween the groups defined by these variables, the rate of stent 
occlusion did not differ significantly (8.6% vs. 1.9%, p = 0°10). 
Logistic regression analysis, including angiographic and hemo- 
static variables, confirmed platelet fibrinogen receptor expression 
as an independent predictor of stent occlusion (p = 0.020). Stent 
occlusion could not be predicted by the time course of any of the 
hemostatic variables. 
Conclusions. Platelet fibrinogen receptor expression is an in- 
dependent predictor of subacute stent occlusion. However, fibrin- 
ogen and F 1 +z concentrations do not show a strong relation to the 
risk of stent occlusion. 
(JAm Coil Cardiol 1996;27:15-21) 
The implantation of an intracoronary stent is an established 
treatment of threatened or present vessel closure after coro- 
nary balloon angioplasty (1-6). Moreover, it has been shown 
by two independent randomized studies (7,8) that in selected 
patients, elective coronary stent implantation improves the 
clinical success rate of balloon angioplasty and reduces the rate 
of restenosis. Despite these favorable results, the specific risks 
of coronary stenting remain a matter of serious concern (9). 
The metal stents that are currently available represent a 
thrombogenic surface that, according to experimental and 
clinical observations (10-12), is thought o necessitate a high 
level of anticoagulation after coronary stenting. Nevertheless, 
even in patients with aggressive anticoagulation, subacute stent 
thromboses occur at a rate of 5% to 17% after emergency 
stenting (1-4,6,10,13-16) and -3.5% after elective stent im- 
plantation (7,8). However, the aggressive anticoagulation reg- 
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imen substantially increases the risk of major bleeding and 
vascular complications (7-10,17-19). 
Tailoring the anticoagulation regimen to the individual 
patient's risk of subacute stent thrombosis may substantially 
improve the clinical outcome of coronary stenting. A number 
of angiographic predictors of subacute stent thrombosis have 
been described (6,13-15). However, conventional hemostatic 
monitoring cannot identify high risk patients after coronary 
stenting (1-3,6). Preliminary reports (20-22) suggest that the 
risk of stent thrombosis can be related to intravascular throm- 
bin formation. In addition, recent studies (9,23,24) have shown 
that the platelet fibrinogen receptor (glycoprotein IIb/IIIa) 
plays a key role in the development of thrombotic omplica- 
tions after coronary interventions. Fibrinogen binding to the 
activated glycoprotein IIb/IIIa represents the final common 
pathway leading to platelet aggregation (25). 
In a prospective trial we investigated novel hemostatic 
predictors of subacute stent thrombosis occurring under strict 
anticoagulation. We hypothesized that subacute stent throm- 
boses are more frequent if, before stent delivery, the patients 
have an elevated surface expression of the inducible platelet 
fibrinogen receptor (glycoprotein IIb/IIIa) or elevated plasma 
concentrations of its ligand or if they show high levels of 
thrombin formation as judged by the plasma concentration of
the prothrombin fragments F~.2. In addition, we investigated 
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Table 1. Clinical Characteristics of Study Patients 
Entire Study Pts With 
Group Subacute Occlusion 
(n = 140) (n : 5) 
Male/female 105/35 5/0 
Age (yr) 
Mean _+ SD 62_+ 11 61 _+ 13 
Range 33- 82 41-75 
Active smokers 63 (45%) 4 
Hypercholesterolemia 108 (77%) 2 
Systemic hypertension 94 (67%) 3 
Diabetes mellitus 20 (14%) 2 
Prior myocardial infarction 73 (52%) 5 
Reduced LV function (EF <50%) 37 (26%) 3 
Unstable angina 101 (72%) 2 
Multivessel disease 84 (60%) 5 
Prior balloon angioplasty 53 (38%) 4 
Data presented are number (%) of patients (Pts), unless otherwise indicated. 
EF = ejection fraction; LV = left ventricular. 
the time course of these variables in relation to subsequent 
stent thrombosis. 
Methods  
Patients. After May 1, 1993, 140 consecutive patients un- 
dergoing coronary stenting for inadequate immediate results 
of balloon angioplasty were recruited for the study. All patients 
received Palmaz-Schatz stents. The indications for coronary 
stenting were inadequate lumen gain (residual stenosis 
->50%), abrupt vessel closure and large dissections (6), the 
latter being the most frequent cause. Patients were not en- 
rolled in the study if they had any hemostatic disorder or other 
contraindication to anticoagulation treatment or if they pre- 
sented with acute myocardial infarction. The baseline character- 
istics of these patients are shown in Table 1. All patients gave 
written informed consent before the qualifying procedure. The 
study was approved by the institute's ethics committee. 
Stenting procedure and poststenting management of the 
patients. Coronary balloon angioplasty was performed by the 
femoral approach. Standard medication for the intervention 
included an initial intraarterial dose of 15,000 IU of heparin 
and additional 5,000 IU for procedures >1 h. Aspirin, 500 mg, 
was injected intravenously during angioplasty. If an inadequate 
lumen could not be managed by the use of larger balloons, or 
if a relevant dissection was visible, decision to stent was made 
early. We tried thereby to avoid severe vessel injury by multiple 
balloon inflations or vessel closure before stenting. Palmaz- 
Schatz stents (Johnson & Johnson Interventional Systems) 
were hand-crimped onto the angioplasty balloon and deployed 
as described in detail earlier (6). If feasible, we optimized stent 
expansion by additional balloon inflations with short balloons 
(10 mm) and high inflation pressures. Within the first 4 h after 
the intervention, we removed the arterial sheath as soon as the 
activated partial prothrombin time decreased to <80 s. 
All patients were started on a standardized anticoagulation 
regimen. Heparin infusion was restarted immediately after 
pressure bandage application and titrated to maintain the 
activated partial prothrombin time between 80 and 150 s. 
Therapy with the vitamin K antagonist phenprocoumon (Mar- 
cumar, Hoffmann-La Roche, Grenzach-Wyhlen, Germany) 
was begun on the day of the intervention. Heparin infusion was 
continued until a stable level of oral anticoagulation was 
achieved at an international normalized ratio for prothrombin 
time between 3.5 and 5.10. The vitamin K antagonist was given 
for 4 weeks. All patients were taking aspirin (2 × 100 mg/day) 
indefinitely while continuing their usual therapy. 
Patients remained in the hospital for 14 days. Only three 
patients demanded to be discharged on day 7 (n = 2) or 8 after 
stenting. Eight weeks after discharge, patients were reassessed 
to monitor subsequent events. 
Study protocol. The study protocol required serial deter- 
mination of hemostatic variables encompassing prothrombin 
time, activated partial prothrombin time, plasma concentra- 
tions of fibrinogen and prothrombin fragments F1 +2 as well as 
the surface xpression on platelets of the inducible fibrinogen 
receptor (glycoprotein lib/Ilia). The first blood sample was 
taken immediately before stent implantation. Thereafter, we 
obtained daily blood samples for 12 days or until subacute 
stent hrombosis. The attending physician had no knowledge of 
the results of the assays on the surface xpression on platelets 
of the inducible fibrinogen receptor (glycoprotein IIb/IIIa) and 
of the plasma concentrations of fibrinogen and prothrombin 
fragments F l +2' 
Quantitative coronary angiography. Quantitative analysis 
was performed as previously described using an automated 
computer-based system (2,3,6). This technique has an inherent 
variability for serial measurements of 0.06 _+ 0.30 mm for 
minimal lumen diameter and 0.09 _+ 0.28 mm for normal 
reference diameters (2,3,6). For analysis, the projection that 
showed the highest grade of stenosis was chosen before and 
after the intervention. 
Flow cytometry. For flow cytometric analysis 1.5 ml of 
blood was collected into a polypropylene syringe containing 
0.5 ml of CPDA (sodium citrate, phosphate buffer, dextrose, 
adenine (Fa. Greiner, Ntirtingen, Germany). Preparation of 
platelets for flow cytometric analysis and immunolabeling of
platelets with monoclonal antibodies was performed as previ- 
ously described (26,27). In brief, within 30 min after blood 
collection, CPDA-anticoagulated whole blood was centrifuged 
at 50 × g for 10 rain to obtain platelet-rich plasma. Thereafter, 
5/zl of platelet-rich plasma was added to polypropylene tubes 
(Becton-Dickinson, Heidelberg, Germany) preloaded with 
45 txl of modified HEPES-Tyrode's buffer containing saturat- 
ing concentrations of fluorescein-isothiocyanite-conjugated 
anti-CD41 monoclonal antibodies (Dianova, Hamburg, Ger- 
many). The antibody is developed against glycoprotein IIb/IIIa 
and detects the glycoprotein irrespective of whether it is in its 
resting or activated form. Nonspecific membrane immunoflu- 
orescence was determined by use of an irrelevant IgG mono- 
clonal antibody. Without agitation, samples were incubated in 
the dark for 15 rain at room temperature. Thereafter, immu- 
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nolabeled samples were fixed by addition of 1 ml of 0.5% 
paraformaldehyde in phosphate-buffered saline, pH 7.4, and 
stored at 4°C before flow cytometric analysis was performed 
within 24 h. We did not fix the platelets before immunostaining 
because we and others (27,28) have found a significantly 
reduced antibody binding to fixed platelets at paraformalde- 
hyde concentrations a low as 0.1%. With constant sampling 
conditions and a narrow time limit for processing of the 
specimens, we did not find any detectable in vitro platelet 
activation under the present experimental protocol (data not 
shown). 
Platelet samples were run on a FACScan cytometer 
(Becton-Dickinson) equipped with a 2-W coherent argon-ion 
laser with an excitation wavelength set at 488 nm. The flow 
cytometer was calibrated with commercially available standard 
fluorescent microbeads (Calibrite, Becton-Dickinson). Fluo- 
rescence and light scatter data were acquired in logarithmic 
mode, and platelets were identified by means of their charac- 
teristic size and granularity in the forward versus right-angle 
light scatter plot. For immunofluorescence analysis, a narrow 
gate was set around the platelet population to exclude red cells 
and cell fragments or background noise as described (26,27). 
Samples were analyzed at a flow rate of between 100 and 200 
events/s, and a total of 5,000 events were acquired and 
analyzed using the FACScan scientific program (Becton- 
Dickinson). Antibody binding was expressed as the mean 
particle fluorescence intensity of the total platelet population 
and was used as a quantitative measure of antigen surface 
expression. The platelet population evaluated was found to be 
->98% positive for platelet-specific CD41 antigen. 
The reference range for CD41 expression on platelets was 
639 to 670 mean fluorescence intensity. In healthy volunteers 
the day to day variability ranged between 1% and 5%, which 
confirms that putative artifacts from in vitro platelet activation 
were consistent throughout the study. 
Other laboratory methods. The plasma concentrations of
the prothrombin fragments FI+ 2 were determined by 
sandwich-type immunoassay (Enzygnost F1+2, Behringwerke 
AG, Marburg, Germany) (20,29). The reference range is <1.1 
nmol/liter, with an interassay coefficient of variation of 6% to 
13%. Fibrinogen concentrations were determined by the 
method of Clauss (30) performed on an automated coagula- 
tion analyzer with turbimetric lot detection (Electra 1000C, 
Baxter, Unterschlei/3heim, Germany). The reference range for 
fibrinogen was 2.0 to 4.5 g/liter, with an interassay coefficient of 
variation of 2% to 5%. 
We measured activated partial prothrombin time and pro- 
thrombin time expressed as an international normalized ratio 
with an automated coagulation analyzer (Electra 1000C, Bax- 
ter) using commercially available reagents (Actin FS, Throm: 
boplastin IS, Baxter). The interassay coefficient of variation 
ranged from 2% to 10% for activated partial prothrombin time 
>120 s and from 2% to 5% for the international normalized 
ratio for prothrombin time. 
Outcome measures. The end point was the incidence of 
subacute occlusive stent thrombosis within 4 weeks after 
stenting. We reasoned that a potential predictor of subacute 
stent thrombosis yielded useful clinical information if the 
majority of stent thromboses occurred in a small subgroup of 
patients characterized by a substantial elevation of this vari- 
able. We therefore prospectively tested the hypothesis that the 
majority of subacute stent hromboses occur in patients whose 
surface xpression of glycoprotein IIb/IIIa on platelets, plasma 
fibrinogen concentration, and plasma immunoreactivity of
FI+2 fell within the range of the upper quartile of the 
distribution of the respective variable within the study popu- 
lation. Given these hypotheses and an expected frequency of 
subacute stent thromboses of 7% (3), the sample size of the 
study allowed detection of significant differences in stent 
thrombosis rate between the groups defined by the presumed 
prognostic variables. 
Statistical analysis. The Kolmogorov-Smirnov test showed 
that the data were not normally distributed. Thus, differences 
among more than two matched samples were tested with 
Friedman's test followed by Wilcoxon's matched-pairs signed- 
rank test. To define variables for subacute occlusion, univariate 
and multivariate analyses were performed. Univariate analyses 
consisted of the chi-square test for categoric variables and 
Mann-Whitney-Wilcoxon rank-sum test for continuous vari- 
ables. Variables with p < 0.15 in the two-tailed test were 
entered into backward stepwise logistic regression analysis 
(SPSS for Macintosh, version 4.0). Values of p < 0.05 in the 
two-tailed test were regarded as significant. 
Resu l ts  
Characteristics of patients with subacute stent thrombosis 
and adherence to anticoagulation regimen. Five subacute 
stent occlusions, proved by emergency angiography, were 
encountered. They presented with acute symptoms at days 3 
(two patients), 4, 6 and 7 after stent implantation (Fig. 1 to 5). 
The main characteristics of patients with subacute stent hrom- 
bosis did not differ significantly from those of the entire study 
group (Table 1). 
Figures 4 and 5 show the time course of the activated partial 
thromboplastin time and of the international normalized ratio 
for prothrombin time in the entire study cohort and in patients 
with subacute stent thrombosis. On 56 treatment days in 37 
patients, activated partial thromboplastin time decreased to 
<80 s despite an international normalized ratio for prothrom- 
bin time <3.5 s. In three of these patients anticoagulation was 
purposely withheld because of hemorrhagic pericardial effu- 
sion (days 1 and 2), reperitoneal hematoma (days 5 to 10) and 
access site bleeding requiring surgical repair (days 3 to 9). 
Stent thrombosis did not occur in any of the patients in whom 
the level of anticoagulation decreased below the desired limit. 
Hemostatic variables before stent implantation and fre- 
quency of stent thrombosis. The distribution of glycoprotein 
IIb/IIIa surface xpression on platelets and those of the plasma 
concentrations of fibrinogen and of F 1 +2 in the entire study 
cohort and in patients with stent thrombosis are shown in 
Figures 1 to 3. All subacute stent occlusions encountered 
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Figure 1. Plot of interquartile range (hatched area) of the surface 
expression of glycoprotein IIb/IIIa on platelets in the entire study 
cohort and of individual values in patients with subacute stent throm- 
bosis. The last individual value represents the last measurement before 
stent thrombosis. Asterisk = days at which the distribution of the 
surface expressions of glycoprotein IIb/Illa on platelets in the entire 
study cohort significantly (p < 0.05) differed from that at day 0. 
during the study occurred within the group of patients whose 
glycoprotein IIb/IIIa surface expression on platelets before 
stent implantation ranked above the 75th percentile. Thus, the 
frequency of stent thrombosis was significantly different be- 
tween the two groups defined by glycoprotein IIb/IIIa surface 
expression on platelets (Table 2). Plasma concentrations of 
fibrinogen and F~ +2 above the 75th percentile before stenting 
were not associated with a significantly elevated rate of stent 
thrombosis as compared to the rest of the patients (Table 2). 
Contribution of angiographic and hemostatic variables to 
estimation of risk of stent thrombosis. On univariate analysis 
of the angiographic and procedural variables, indication for 
stenting (abrupt vessel closure), as well as minimal lumen 
Figure 2. Plot of interquartile range (hatched area) of the fibrinogen 
concentration in the entire study cohort and of individual values in 
patients with subacute stent thrombosis. The last individual value 
represents the last measurement before stent thrombosis. Asterisk = 
days at which the distribution of fibrinogen concentrations in the entire 
study cohort significantly (p < 0.05) differed from that at day 0. 
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Figure 3. Plot of interquartile range (hatched area) of the concentra- 
tion of the prothrombin fragments F~+ 2 in the entire study cohort and 
of individual values in patients with subacute stent thrombosis. The 
last individual value represents the last measurement before stent 
thrombosis. Asterisk = days at which the distribution of F 1+2 concen- 
trations in the entire study cohort significantly (p < 0.05) differed from 
that at day 0. 
diameter and percent diameter stenosis before the procedure 
were significantly related to subacute stent occlusion (Table 3). 
Minimal lumen diameter and percent diameter stenosis after 
the procedure were related to stent occlusion by trend (Table 
3). Backward stepwise logistic regression analysis of these 
angiographic variables together with the hemostatic variables 
identified glycoprotein IIb/IIIa surface expression on platelets 
(p = 0.020), final minimal lumen diameter (p = 0.041) and 
abrupt vessel closure before stenting (p = 0.012) as indepen- 
dent predictors of subacute stent thrombosis. 
Time course of hemostatic variables in entire study group 
and in patients with stent thrombosis. In the entire study 
cohort, plasma fibrinogen concentrations increased (Fig. 2), 
Figure 4. Plot of interquartile range (hatched area) of the activated 
partial thromboplastin time (aPTT) in the entire study cohort and of 
individual values in patients with subacute stent thrombosis. The last 
individual value represents the last measurement before stent throm- 
bosis. 
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Figure 5. Plot of the interquartile range (hatched area) of the 
concentration of the international normalized ratio for prothrombin 
time in the entire study cohort and of individual values in patients with 
subacute stent hrombosis. The last individual value represents he last 
measurement before stent thrombosis. 
and Fa+ 2 concentrations decreased (Fig. 3) after stent implan- 
tation. Compared with its interindividual variation (variation 
coefficient 5.1%), surface expression of glycoprotein IIb/IIIa 
showed only minor intraindividual changes throughout the 
study (Fig. 1). In the entire study cohort, surface xpression of 
glycoprotein IIb/IIIa peaked on day 3, and the median relative 
increase from before stenting to day 3 amounted to 1.2% 
(interquartile range -1.3% to 3.6%). 
In patients with subsequent stent hrombosis, the glycopro- 
tein IIb/IIIa surface expression on platelets essentially re- 
mained elevated throughout the study (Fig. 1). During the days 
before stent thrombosis, fibrinogen concentrations increased 
to a similar extent as in the entire study group (Fig. 2). A 
specific pattern in the time course of FI+ 2 concentrations was 
not detected after stent delivery (Fig. 3). FI+ 2 concentrations 
were above normal range in all patients at some time before 
stent thrombosis. However, temporary elevations of Ft+ 2 
concentrations above normal range also occurred in 68 pa- 
tients (50.4%) without subsequent stent thrombosis. More- 
over, stent thrombosis was not preceded by a consistent 
increase in FI+ 2 concentration, and in all patients with stent 
thrombosis F1+2 concentrations were within normal range 
before the event (Fig. 3). 
Table 2. Rate of Subacute Stent Thrombosis inGroups Defined by 
Hemostatic Variables 
Above Below 
Upper Upper p 
Quartile Quartile Value 
Surface xpression on platelets of 5/35 (14.2%) 0/105 (0%) 0.0008 
glycoprotein IIb/IIIa 
Concentration of prothrombin 3/35 (8.6%) 2/105 (1.9%) 0.10 
fragments F]-2 
Fibrinogen concentration 3/35 (8.6%) 2/105 (1.9%) 0.10 
Data presented are number (%) of patients. 
Table 3. Procedural Characteristics and Angiographic Results 
Entire Study Pts With Subacute p 
Group Occlusion Value 
Indication for stenting 0.0001 
Abrupt closure 3 (2%) 2 
Dissection 123 (88%) 3 
Inadequate lumen gain 14 (10%) 0 
Stent localization 0.30 
LAD 61 (44%,) 1 
LCx 19 (14%) 2 
RCA 51 (36%) 2 
Venous bypass graft 9 (6%) 0 
Multiple stents 46 (33%) 3 0.41 
Reference diameter ( am) 3.31 _+ 0.53 3.11 +_ 0.81 0.27 
Minimal lumen diameter 
Before stenting 0.63 +_ 0.47 0.18 _+ 0.39 0.001 
After stenting 2.96 + 0.50 2.56 _+ 0.68 0.12 
Diameter stenosis 
Before stenting 80 _+ 15 94 _+ 14 0.01 
After stenting 10 +_ 11 18 _+ 9 0.08 
Maximal inflation pressure (atm) 12.3 + 2.1 12.0 _+ 1.4 0.54 
Balloon/vessel ratio 0.97 + 0.15 1.02 + 0.13 0.41 
Data presented are mean value + SD or number (%) of patients (Pts); p 
values refer to the difference between the groups with and without stent 
thrombosis. LAD = left anterior descending coronary artery'; LCx - left 
circumflex coronary artery; RCA - right coronary artery. 
Discussion 
To our knowledge, the present study is the first to identify 
prospectively an independent hemostatic predictor of subacute 
occlusive stent thrombosis. The surface expression of the 
inducible fibrinogen receptor (glycoprotein IIb/IIIa) on plate- 
lets, determined immediately before stent delivery, discrimi- 
nates a subgroup of patients with an increased rate of subse- 
quent stent occlusion. According to the predefined outcome 
measure, all of the five stent hromboses ncountered through- 
out the study occurred within the quarter of the study cohort 
with the highest surface expression of glycoprotein lib/Ilia on 
platelets. The argument is strengthened bylogistic regression 
analysis, demonstrating that the predictive power of increased 
surface expression of glycoprotein lib/Ilia on platelets is 
independent of concomitant angiographic risk factors of sub- 
acute stent hrombosis and of other hemostatic variables. 
In addition, the present study demonstrates that monitoring 
the activation of coagulation by determination of the pro- 
thrombin fragments Fl +2 does not yield clinically useful infor- 
mation about he risk of subsequent occlusive stent hrombo- 
sis. Elevated concentrations of the prothrombin fragments 
Ft+ 2 before stent delivery did not identify a subgroup with a 
substantially increased rate of subsequent stent thrombosis. 
Moreover, stent occlusion is not preceded by consistent in- 
creases in F1+2 concentrations. On the contrary, in every case 
of stent hrombosis, F1+2 concentrations were within normal 
range before the event. 
The present study tested potential predictors of occlusive 
stent hrombosis n a clinical setting with a low rate of subacute 
stent closures. The number of occlusive stent hromboses that 
20 NEUMANN ETA[. .  JACC Vol. 27, No. l 
HEMOSTATIC PREDICTORS OF STENT THROMBOSIS January 1996:15-21 
occurred uring the study period was substantially ower than 
expected and approached that in recent trials on elective 
stenting (7,8). There are several potential reasons for this 
advantageous outcome: 1) As a result of favorable xperience 
with coronary stenting (6-8), the indication changed from true 
rescue situations to the improvement of suboptimal angio- 
plasty results. Abrupt vessel closure, therefore, was a rare 
indication for stenting. 2) We used high inflation pressures (31) 
and always took care to cover the entire dissection with a stent, 
using multiple stents in almost 33% of the patients. These 
measures may have improved stent delivery (31) and, thus, 
diminished the rate of subacute stent thrombosis. 
Platelet fibrinogen receptor and its ligand. The glycopro- 
tein IIb/IIIa complex is the most abundant receptor on the 
platelet membrane and is constitutively expressed on all nor- 
mal platelets (25). Even maximal stimulation increases surface 
expression of glycoprotein IIb/IIIa on platelets by only 10% to 
20% through translocation from canalicular and alpha-granule 
stores. Aspirin does not affect degranulation of platelet adhe- 
sion receptors (32). On platelets at rest, the glyeoprotein 
IIbflIIa complex is present in an inactivated state. Stimulation 
of platelets converts glycoprotein IIb/IIIa to its activated state, 
which can bind its major ligand fibrinogen (25). A number of 
agonists can achieve this, even if the cyclooxygenase pathway is 
effectively blocked by aspirin (25). Fibrinogen binding to the 
activated glycoprotein IIb/IIIa is the final common pathway 
leading to platelet aggregation (25). 
In the present study, we used anti-CD41 antibodies that 
detect the glycoprotein IIb/IIIa complex irrespective of 
whether it is in its resting or activated form. Anti-CD41 
immunofluorescence, therefore, does not indicate platelet 
activation but reflects the propensity of platelets to respond to 
local stimuli and induce thrombosis. Consistent with the notion 
that glycoprotein IIb/IIIa is constitutively expressed on plate- 
lets, the glycoprotein IIb/IIIa surface expression on platelets 
showed little variation over time compared to the interindi- 
vidual variation. Hence, glycoprotein IIb/IIIa surface expres- 
sion may be considered as a patient characteristic. The study, 
therefore, demonstrates for the first time a patient-related 
variable that, in addition to known site-related variables, 
modulates the risk of subacute stent thrombosis. 
Fibrinogen is the major ligand of activated glycoprotein 
IIb/IIIa and represents the final substrate of the coagulation 
cascade (25). By large-scale epidemiologie studies, plasma 
fibrinogen has been identified as an independent risk factor for 
adverse cardiovascular events (33,34). Nevertheless, neither 
the baseline value of the fibrinogen concentration or its 
subsequent change in time showed asignificant relation to risk 
of subacute stent closure. However, the low rate of stent 
thrombosis limits the statistical power of these negative find- 
ings. We therefore cannot exclude weak relations between the 
plasma concentrations of fibrinogen and the risk of stent 
thrombosis. Despite this limitation, the study suggests that the 
inducible platelet fibrinogen receptor is superior to its ligand in 
predicting subacute stent occlusion. 
Thrombin formation. Inadvertently or intentionally re- 
duced levels of anticoagulation in a sizable number of patients 
did not prompt stent hromboses. This observation emphasizes 
the inefficiency of conventional hemostatic monitoring for 
identifying high risk patients after coronary stenting (1-3,6). 
More direct information on the adequacy of the anticoagula- 
tion level may be obtained by analyzing intravascular thrombin 
formation (20). 
The prothrombin fragments FI+ 2 have been proved to be 
sensitive markers of intravascular thrombin formation 
(20,29,35). We speculated that the thrombogenicity of the 
dilated plaque may be assessed by measuring the systemic F1 +2 
concentration and that this may predict he risk of subsequent 
thrombotic occlusion after a stent has been implanted. Con- 
sistent with a previous report (35), the peri-interventional F 1+2 
concentrations are elevated in a substantial number of pa- 
tients. The rate of subsequent stent hrombosis, however, is not 
significantly increased in these patients. Together with the 
consistent results of the logistic regression analysis, this pre- 
cludes a relation between the risk of stent thrombosis and 
peri-interventional thrombin formation that is strong enough 
to guide the clinical management. Again, the limited statistical 
power of the study as a result of the low number of stent 
thromboses prevents us from excluding a weak relation be- 
tween the FI+ 2 concentration and the risk of stent occlusion. 
During the first week after stenting, even high levels of 
anticoagulation did not suppress thrombin formation ade- 
quately in a substantial number of patients. This is shown by 
the time course of the distribution of FI+ 2 concentrations. 
Other investigators described increases in the systemic FI+ 2 
concentrations that preceded stent thrombosis (22) and used 
F1+2 concentrations to guide anticoagulation therapy after 
coronary stenting (21). These reports led us to test the 
hypothesis that daily measurements of Fl+ 2 concentrations 
may help to detect imminent stent thrombosis. However, the 
present study does not confirm the earlier anecdotal reports. 
We therefore cannot recommend the routine determination of
the prothrombin fragments F1+2 after coronary stent implan- 
tation. 
Clinical perspectives. The present study demonstrates a 
relation between the surface xpression of the inducible fibrin- 
ogen receptor on platelets and the risk of subacute occlusive 
stent thrombosis. However, coagulation parameters did not 
yield equally useful information about the risk of subacute 
stent hrombosis. On the basis of these findings, it is tempting 
to speculate that the platelet plays a more central role in 
subacute stent thrombosis than the coagulation system. The 
results of the present study challenge the established antico- 
agulation regimen for patients with newly implanted coronary 
stents (11) and emphasize the development of more effective 
antiplatelet strategies (9,24,36). 
In addition to angiographic variables, the determination of
the surface expression of the fibrinogen receptor on platelets 
may help to tailor the anticoagulation therapy after coronary 
stenting to the individual patient's needs. For those at low risk 
of stent thrombosis, inhibition of the coagulation may be 
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dispensable, a practice already pursued by a number of groups 
(37-39). Conversely, those at high risk will need a more 
aggressive antithrombotic treatment. In the future this treat- 
ment may not involve high doses of heparin and warfarin (11); 
rather, treatment may include selective inhibition of the plate- 
let fibrinogen receptor (9) with specific antagonists, uch as the 
chimeric Fab fragment c7E3 or peptide as well as nonpeptide 
blocking agents (23,24). 
The assistance of Silja R~idiger for the documentation f the clinical data is 
highly appreciated. We thank Kathrin Gloth for excellent echnical assistance. 
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